Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials?

Journal of Medical Screening

Volumn 3, Issue 1, 1996, Pages 12-17

  Palomaki, Glenn E ^a  

^a FOUNDATION FOR BLOOD RESEARCH   (United States)

Author keywords

Down's syndrome; Human chorionic gonadotrophin; Intervention trials; Prenatal screening; Risk

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL;

ADULT; AGE DISTRIBUTION; AMNIOCENTESIS; ARTICLE; CLINICAL TRIAL; DOWN SYNDROME; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MATERNAL AGE; META ANALYSIS; METHODOLOGY; PREGNANCY; PRENATAL DIAGNOSIS; RISK FACTOR; SECOND TRIMESTER PREGNANCY; STANDARD; STATISTICAL MODEL; STATISTICS;

ADULT; AGE DISTRIBUTION; ALPHA-FETOPROTEINS; AMNIOCENTESIS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; ESTRIOL; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MATERNAL AGE; MODELS, STATISTICAL; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RISK FACTORS;

EID: 0030345675     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1177/096914139600300105     Document Type: Article

References (2)

1. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. NEnglJMcd 1992;327:588-93.
2. Wald NJ, Kennard A, Densem JV, CuckJe HS, Chard T, Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 1992; 305:391-4.